Abstracts

CheckMate 649 (NCT02872116) is a randomized, open-label phase 3 study as first-line (1L) therapy for patients (pts) with GC/GEJC/EAC. Primary results showed statistically significant impr...

06/25/2023

Phase III study of NUC-1031 + cisplatin vs gemcitabine + cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121)

Biliary tract cancer (BTC) carries a poor prognosis with limited treatment options. The accepted global standard of care chemotherapy backbone is gemcitabine + cisplatin (GemCis). NUC-103...

06/25/2023

Additional data from the KEYNOTE-859 study of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer

The phase 3 KEYNOTE-859 study (NCT03675737) showed that adding pembrolizumab to chemotherapy significantly improved the primary endpoint of OS (median 12.9 months vs 11.5 months; HR 0.78,...

06/25/2023

GEMSTONE-304: A phase 3 study of sugemalimab plus chemotherapy versus chemotherapy as first-line treatment of patients with unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC)

Although anti-programmed death 1 (PD-1) antibody plus chemotherapy has recently been approved for first-line (1L) ESCC, anti-programmed death-ligand 1 (PD-L1) antibody may offer another c...

06/25/2023

Integrating trastuzumab (T), with or without pertuzumab (P), into perioperative chemotherapy (CT) of HER-2+ gastric cancer (GC) - subgroup analyses of EORTC 1203 “INNOVATION”, a collaboration with KCSG and DUCG

10-20% of GC are HER-2 positive. The role of perioperative anti-HER2-directed treatment is yet undefined.

06/25/2023

EORTC 1707 VESTIGE: Adjuvant immunotherapy in patients (pts) with resected gastroesophageal adenocarcinoma (GEA) following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1)—an open-label randomized controlled phase II study

GEA pts with tumor-positive lymph nodes (ypN+) or incomplete surgical resection (R1) following neoadjuvant chemotherapy (chemo) are high risk for relapse. Adjuvant nivolumab is effective ...

06/25/2023

Liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma: Sensitivity analysis of survival from the NAPOLI 3 trial

Liposomal irinotecan and 5-fluorouracil/leucovorin (5-FU/LV) is approved in the USA and Europe for the treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) after progression w...

D. Melisi ;

Eric Van Cutsem , MD, PhD;

06/25/2023

Abstracts

High-scoring SAWC Spring Abstracts

06/01/2023

A selection of some of the top-scoring abstracts presented at SAWC Spring 2023, held in National Harbor, MD, from April 26-30.

A selection of some of the...

06/01/2023

Wounds

Thrombectomy: Features

Read more about Thrombectomy: Features
58 views

ISET 2023 ABSTRACT

Safety and Performance of Aspiration Thrombectomy for Lower Extremity Acute Limb Ischemia: STRIDE Interim Analysis

01/17/2023

Adam Powell , MD;

T. Maldonado ;

K. Nagarsheth ;

J. Rowse ;

Jessica A. Chung ;

Purpose: In a recent meta-analysis, the reported rate of 30-day limb salvage in patients with acute limb ischemia (ALI) after surgical intervention was 83.1%. The purpose of this interim analysis is to report safety and performance data from...

Purpose: In a recent...

01/17/2023

Vascular Disease Management